{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:52:31Z","timestamp":1785214351425,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10067-020-05073-9","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T06:02:47Z","timestamp":1586498567000},"page":"2055-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Rheumatologists\u2019 perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-6018","authenticated-orcid":false,"given":"Armen Yuri","family":"Gasparyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-8486","authenticated-orcid":false,"given":"Olena","family":"Zimba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"5073_CR1","unstructured":"COVID-19 cases worldwide. https:\/\/www.worldometers.info\/coronavirus\/. Accessed on 29 Mar 2020"},{"key":"5073_CR2","doi-asserted-by":"publisher","unstructured":"Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2002032","DOI":"10.1056\/NEJMoa2002032"},{"key":"5073_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15171\/ijoem.2020.1921","volume":"11","author":"P Habibzadeh","year":"2020","unstructured":"Habibzadeh P, Stoneman EK (2020) The novel coronavirus: a Bird's eye view. Int J Occup Environ Med 11:65\u201371. https:\/\/doi.org\/10.15171\/ijoem.2020.1921","journal-title":"Int J Occup Environ Med"},{"key":"5073_CR4","unstructured":"COVID-19 Situation report 68 by the World Health Organization. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200328-sitrep-68-covid-19.pdf?sfvrsn=384bc74c_2.2. Updated on 28 March 2020. Accessed on 29 Mar 2020"},{"key":"5073_CR5","doi-asserted-by":"publisher","unstructured":"Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (2020) Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/s1473-3099(20)30195-x","DOI":"10.1016\/s1473-3099(20)30195-x"},{"key":"5073_CR6","doi-asserted-by":"publisher","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. https:\/\/doi.org\/10.1016\/s2213-2600(20)30116-8","DOI":"10.1016\/s2213-2600(20)30116-8"},{"key":"5073_CR7","doi-asserted-by":"publisher","unstructured":"Yang J, Zheng Y, Gou X et al (2020) Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.017","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"5073_CR8","doi-asserted-by":"publisher","unstructured":"Liu W, Tao ZW, Lei W et al (2020) Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. https:\/\/doi.org\/10.1097\/cm9.0000000000000775","DOI":"10.1097\/cm9.0000000000000775"},{"key":"5073_CR9","doi-asserted-by":"publisher","unstructured":"Cai H (2020) Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. https:\/\/doi.org\/10.1016\/s2213-2600(20)30117-x","DOI":"10.1016\/s2213-2600(20)30117-x"},{"key":"5073_CR10","unstructured":"Environmental issues in Iran. https:\/\/www.theguardian.com\/world\/iran-blog\/2014\/nov\/21\/iran-environmental-consequences-of-sanctions. Updated 2014. Accessed on 19 Mar 2020"},{"key":"5073_CR11","unstructured":"Report of the WHO-China Joint Mission on Coronavirus Disease 19 (COVID-19). Available at https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19%2D%2D-final-report-1100hr-28feb2020-11mar-update.pdf?sfvrsn=1a13fda0_2&download=true. Updated 28 February 2020. Accessed on 24 Mar 2020"},{"key":"5073_CR12","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.3346\/jkms.2020.35.e61","volume":"35","author":"JY Kim","year":"2020","unstructured":"Kim JY, Choe PG, Oh Y et al (2020) The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci 35:e61. https:\/\/doi.org\/10.3346\/jkms.2020.35.e61","journal-title":"J Korean Med Sci"},{"key":"5073_CR13","doi-asserted-by":"publisher","unstructured":"Lippi G, Plebani M, Michael Henry B (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. https:\/\/doi.org\/10.1016\/j.cca.2020.03.022","DOI":"10.1016\/j.cca.2020.03.022"},{"key":"5073_CR14","doi-asserted-by":"publisher","unstructured":"Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa248","DOI":"10.1093\/cid\/ciaa248"},{"key":"5073_CR15","doi-asserted-by":"publisher","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(20)30628-0","DOI":"10.1016\/s0140-6736(20)30628-0"},{"key":"5073_CR16","doi-asserted-by":"publisher","unstructured":"Clerkin Kevin J, Fried Justin A, Raikhelkar J et al (2020) Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046941","DOI":"10.1161\/CIRCULATIONAHA.120.046941"},{"key":"5073_CR17","doi-asserted-by":"publisher","unstructured":"Driggin E, Madhavan MV, Bikdeli B et al (2020) Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 27204. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.031","DOI":"10.1016\/j.jacc.2020.03.031"},{"key":"5073_CR18","doi-asserted-by":"publisher","unstructured":"Hu H, Ma F, Wei X, Fang Y (2020) Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa190","DOI":"10.1093\/eurheartj\/ehaa190"},{"key":"5073_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/cs20200163","volume":"134","author":"D Batlle","year":"2020","unstructured":"Batlle D, Wysocki J, Satchell K (2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 134:543\u2013545. https:\/\/doi.org\/10.1042\/cs20200163","journal-title":"Clin Sci (Lond)"},{"key":"5073_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","volume":"12","author":"H Xu","year":"2020","unstructured":"Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12:8. https:\/\/doi.org\/10.1038\/s41368-020-0074-x","journal-title":"Int J Oral Sci"},{"key":"5073_CR21","doi-asserted-by":"publisher","unstructured":"Day M (2020) Covid-19: European drugs agency to review safety of ibuprofen. 368:m1168. https:\/\/doi.org\/10.1136\/bmj.m1168","DOI":"10.1136\/bmj.m1168"},{"key":"5073_CR22","doi-asserted-by":"publisher","first-page":"m1086","DOI":"10.1136\/bmj.m1086","volume":"368","author":"M Day","year":"2020","unstructured":"Day M (2020) Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. Bmj 368:m1086. https:\/\/doi.org\/10.1136\/bmj.m1086","journal-title":"Bmj"},{"key":"5073_CR23","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"5073_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"5073_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14:58\u201360. https:\/\/doi.org\/10.5582\/ddt.2020.01012","journal-title":"Drug Discov Ther"},{"key":"5073_CR26","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","volume":"35","author":"J Lim","year":"2020","unstructured":"Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35:e79. https:\/\/doi.org\/10.3346\/jkms.2020.35.e79","journal-title":"J Korean Med Sci"},{"key":"5073_CR27","doi-asserted-by":"publisher","unstructured":"Emanuel EJ, Persad G, Upshur R et al (2020) Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMsb2005114","DOI":"10.1056\/NEJMsb2005114"},{"key":"5073_CR28","doi-asserted-by":"publisher","unstructured":"Cao B, Wang Y, Wen D et al (2020) A trial of Lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2001282","DOI":"10.1056\/NEJMoa2001282"},{"key":"5073_CR29","doi-asserted-by":"publisher","unstructured":"Baden LR, Rubin EJ (2020) Covid-19 \u2014 the search for effective therapy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMe2005477","DOI":"10.1056\/NEJMe2005477"},{"key":"5073_CR30","doi-asserted-by":"publisher","unstructured":"Cai Q, Yang M, Liu D et al (2020) Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"5073_CR31","doi-asserted-by":"publisher","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain JM, Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 55:105923. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105923","journal-title":"Int J Antimicrob Agents"},{"key":"5073_CR32","doi-asserted-by":"publisher","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. https:\/\/doi.org\/10.5582\/bst.2020.01047","DOI":"10.5582\/bst.2020.01047"},{"key":"5073_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"5073_CR34","doi-asserted-by":"publisher","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. https:\/\/doi.org\/10.1016\/j.jcrc.2020.03.005","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"5073_CR35","doi-asserted-by":"publisher","unstructured":"Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 105932. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105932","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"key":"5073_CR36","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"5073_CR37","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/jac\/dkw591","volume":"72","author":"JW Mason","year":"2017","unstructured":"Mason JW (2017) Antimicrobials and QT prolongation. J Antimicrob Chemother 72:1272\u20131274. https:\/\/doi.org\/10.1093\/jac\/dkw591","journal-title":"J Antimicrob Chemother"},{"key":"5073_CR38","unstructured":"Indian Council of Medical Research guidelines for use of empirical use of hydroxychloquine prophylaxis in COVID-19. https:\/\/icmr.nic.in\/sites\/default\/files\/upload_documents\/HCQ_Recommendation_22March_final_MM_V2.pdf. Updated 23 March 2020, Accessed on 24 Mar 2020"},{"key":"5073_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zeron P, Bombardieri S et al (2020) EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis 79:3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114","journal-title":"Ann Rheum Dis"},{"key":"5073_CR40","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/s0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30\u2013e31. https:\/\/doi.org\/10.1016\/s0140-6736(20)30304-4","journal-title":"Lancet"},{"key":"5073_CR41","doi-asserted-by":"crossref","unstructured":"Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with Tocilizumab.[ChinaXiv:202003.00026]. Available at http:\/\/www.chinaxiv.org\/abs\/202003.00026. Updated on 05 March 2020. Accesed on 29 Mar 2020","DOI":"10.1073\/pnas.2005615117"},{"key":"5073_CR42","unstructured":"Approval for tocilizumab use in severe Covid-19 in China. https:\/\/www.pharmaceutical-technology.com\/news\/roche-actemra-coronavirus-complications\/. Updated 05 March 2020. Accessed on 19 Mar 2020"},{"key":"5073_CR43","unstructured":"Trial in interleukin-6 blockade with sarilumab for Covid-19. https:\/\/www.clinicaltrialsarena.com\/news\/sanofi-regeneron-trial-kevzara-covid-19\/. Updated 16 March 2020. Accessed on 19 Mar 2020"},{"key":"5073_CR44","doi-asserted-by":"publisher","unstructured":"Fan HH, Wang LQ, Liu WL et al (2020) Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J. https:\/\/doi.org\/10.1097\/cm9.0000000000000797","DOI":"10.1097\/cm9.0000000000000797"},{"key":"5073_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14787210.2020.1706483","volume":"18","author":"RML Colunga Biancatelli","year":"2020","unstructured":"Colunga Biancatelli RML, Berrill M, Marik PE (2020) The antiviral properties of vitamin C. Expert Rev Anti-Infect Ther 18:99\u2013101. https:\/\/doi.org\/10.1080\/14787210.2020.1706483","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"5073_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fimmu.2019.00065","volume":"10","author":"N Goncalves-Mendes","year":"2019","unstructured":"Goncalves-Mendes N, Talvas J, Duale C et al (2019) Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial. Front Immunol 10:65. https:\/\/doi.org\/10.3389\/fimmu.2019.00065","journal-title":"Front Immunol"},{"key":"5073_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41430-020-0564-0","volume":"74","author":"WB Grant","year":"2020","unstructured":"Grant WB, Al Anouti F, Moukayed M (2020) Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits. Eur J Clin Nutr 74:366\u2013376. https:\/\/doi.org\/10.1038\/s41430-020-0564-0","journal-title":"Eur J Clin Nutr"},{"key":"5073_CR48","doi-asserted-by":"publisher","unstructured":"Grant WB, Lahore H, McDonnell SL et al (2020) Vitamin D supplementation could prevent and treat influenza, coronavirus, and pneumonia infections. Preprints 2020030235 https:\/\/doi.org\/10.20944\/preprints202003.0235.v1","DOI":"10.20944\/preprints202003.0235.v1"},{"key":"5073_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395:473\u2013475. https:\/\/doi.org\/10.1016\/S0140-6736(20)30317-2","journal-title":"Lancet"},{"key":"5073_CR50","unstructured":"EULAR guidance for patients during Covid-19 outbreak. https:\/\/www.eular.org\/eular_guidance_for_patients_covid19_outbreak.cfm. Updated 17 March 2020. Accessed on 19 Mar 2020"},{"key":"5073_CR51","unstructured":"BSR guidance for patients during Covid-19 outbreak. https:\/\/www.rheumatology.org.uk\/News-Policy\/Details\/Covid19-Coronavirus-update-members. Updated 25 March 2020. Accessed on 29 Mar 2020"},{"key":"5073_CR52","unstructured":"ACR guidance for patients during Covid-19 outbreak. https:\/\/www.rheumatology.org\/announcements. Updated 28 March 2020. Accessed on 29 Mar 2020"},{"key":"5073_CR53","unstructured":"Australian Rheumatology Association guidance for patients during Covid-19 outbreak. https:\/\/arthritisaustralia.com.au\/advice-regarding-coronavirus-covid-19-from-the-australian-rheumatology-association\/. Updated 17 March 2020. Accessed on 19 Mar 2020"},{"key":"5073_CR54","doi-asserted-by":"publisher","unstructured":"van Doremalen N, Bushmaker T, Morris DH et al (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMc2004973","DOI":"10.1056\/NEJMc2004973"},{"key":"5073_CR55","doi-asserted-by":"publisher","unstructured":"Wilder-Smith A, Freedman DO (2020) Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med 27. https:\/\/doi.org\/10.1093\/jtm\/taaa020","DOI":"10.1093\/jtm\/taaa020"},{"key":"5073_CR56","doi-asserted-by":"publisher","unstructured":"Kwon KT, Ko J-H, Shin H, Sung M, Kim JY (2020) Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci 35:e123. https:\/\/doi.org\/10.3346\/jkms.2020.35.e123","DOI":"10.3346\/jkms.2020.35.e123"},{"key":"5073_CR57","doi-asserted-by":"publisher","unstructured":"Li R, Pei S, Chen B, et al. (2020) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Science eabb3221. https:\/\/doi.org\/10.1126\/science.abb3221","DOI":"10.1126\/science.abb3221"},{"key":"5073_CR58","doi-asserted-by":"publisher","unstructured":"Wu Y, Guo C, Tang L et al (2020) Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/s2468-1253(20)30083-2","DOI":"10.1016\/s2468-1253(20)30083-2"},{"key":"5073_CR59","doi-asserted-by":"publisher","unstructured":"Adnan Shereen M, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2020.03.005","DOI":"10.1016\/j.jare.2020.03.005"},{"key":"5073_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1086\/524065","volume":"197","author":"V Andreasen","year":"2008","unstructured":"Andreasen V, Viboud C, Simonsen L (2008) Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. J Infect Dis 197:270\u2013278. https:\/\/doi.org\/10.1086\/524065","journal-title":"J Infect Dis"},{"key":"5073_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/trf.14422","volume":"58","author":"SI Hindawi","year":"2018","unstructured":"Hindawi SI, Hashem AM, Damanhouri GA, el-Kafrawy SA, Tolah AM, Hassan AM, Azhar EI (2018) Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet a light. Transfusion 58:52\u201359. https:\/\/doi.org\/10.1111\/trf.14422","journal-title":"Transfusion"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05073-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05073-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05073-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:14:09Z","timestamp":1666311249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05073-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5073"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05073-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Durga Prasanna Misra declares that he has no conflict of interest, including no relationship with pharmaceutical companies.Vikas Agarwal declares that he has no conflict of interest, including no relationship with pharmaceutical companies.Olena Zimba declares that she has no conflict of interest, including no relationship with pharmaceutical companies.Armen Yuri Gasparyan declares that he has no conflict of interest, including no relationship with pharmaceutical companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any institution or association.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}